Latest Omeros Corporation Stories
- Data Bode Well for Success of Ongoing Phase 2 Trial in Thrombotic Microangiopathies - SEATTLE, Nov.
-- Omidria(TM) U.S. Commercial Launch Planned for Early 2015 -- SEATTLE, Nov.
-- Unique Billing Code Allows Separate Payment for Omidria -- SEATTLE, Oct.
-- Enrollment in Huntington's Trial Suspended Pending Further Assessment of Preclinical Data -- SEATTLE, Oct.
-- FDA Approval of Omidria(TM) Received on May 30, 2014 - SEATTLE, Aug.
-- Omeros to Host Conference Call Today at 4:30 p.m. ET -- SEATTLE, June 2, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the U.S.
-- Secures Additional $50.4 Million in Cash in 1Q 2014 -- SEATTLE, May 12, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering,
SEATTLE, April 7, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation,
- A person in a secondary role, specifically the second most important character (after the protagonist).